newsfilter
← Earnings
Earnings Releases·

Neumora Therapeutics — Third Quarter 2026 Earnings Summary

Neumora Therapeutics submitted an Investigational New Drug application for its NLRP3 inhibitor, NMRA-215, to treat obesity and cardiometabolic disease. The company reported dose-proportional increases in exposure for NMRA-511 at a 30 mg BID dose in healthy elderly participants, indicating potential to enhance the efficacy observed in previous Phase 1b studies. For the third quarter ended September 30, 2026, Neumora reported a net loss of $34.4 million and ended the period with $85.7 million in cash and cash equivalents.

Company
NEUMORA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology